|
CA3106983A1
|
|
Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment
|
|
US2019262432A1
|
|
Treatment of middle east respiratory syndrome coronavirus
|
|
WO2016200916A1
|
|
Treatment of human metapneumovirus
|
|
CN107135653A
|
|
Colicine variant
|
|
US2017290893A1
|
|
Treatment of infection by human enterovirus D68
|
|
AU2015215955A1
|
|
Technology for preparation of macromolecular microspheres
|
|
WO2015184356A1
|
|
Treatment of middle east respiratory syndrome coronavirus
|
|
US2016120961A1
|
|
Treatment of merkel cell polyomavirus infection
|
|
WO2014201034A2
|
|
Treatment for polyomavirus infection
|
|
WO2014197485A1
|
|
Anti-viral therapeutic for infection of the eye
|
|
EP2970857A2
|
|
Novel method of protein purification
|
|
EP2968189A1
|
|
Methods for preparing injectable protein microparticle suspensions
|
|
AU2013237761A1
|
|
Technology for preparation of macromolecular microspheres
|
|
WO2014005103A2
|
|
Microparticle formulations for delivery to the lower and central respiratory tract and methods of manufacture
|
|
EP2877204A2
|
|
Microparticle formulations for delivery to the upper and central respiratory tract and methods of manufacture
|
|
CN109529026A
|
|
For treating method, compound and the composition of influenza and parainfluenza patient
|
